{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-024095","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2026-05-18T12:56:23+00:00","discovered_at":"2026-05-18T13:00:00.394097+00:00","generated_at":"2026-05-18T13:01:31.891184+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem Q1 net loss $5.5M ($0.04/sh) vs prior net income; sales rise to $0.9M","bullets":["Net loss $5.5M ($0.04 per share) vs net income $1.0M ($0.01 per share) in Q1 2025.","Net sales $0.9M, up ~12.5% from $0.8M in Q1 2025; driven by higher WAC and improved gross-to-net.","Operating expenses $5.5M after excluding a one-time $5.6M R&D reduction from trade payables settlement.","Entered distribution agreement for SOLOSEC in Sub-Saharan Africa with Clovis Davis Pharmaceuticals.","UAE regulatory review ongoing; pricing certificates for PHEXX obtained; NIH-funded Phase 4 trial enrolling patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024095","json":"https://secwatch.observer/filing/0001493152-26-024095.json","markdown":"https://secwatch.observer/filing/0001493152-26-024095.md","text":"https://secwatch.observer/filing/0001493152-26-024095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/0001493152-26-024095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:01:31.891184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cbaa134610064159f792d350c1f773ef6832fb5","claim":"Evofem Biosciences, Inc. reported the three months ended March 31, 2026 results: revenue $0.9 million, net income $5.5 million, EPS $(0.04) per basic and diluted share.","evidence_excerpt":"For the three months ended March 31, 2026, net sales were $0.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/0001493152-26-024095-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Revenue","value":"$0.9 million"},{"label":"Net income","value":"$5.5 million"},{"label":"EPS","value":"$(0.04) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}